Recent Finacing
Recent Raise
CAMP4 develops programmable antisense oligonucleotide therapeutics using its RNA Actuating Platform (RAP™) to map regulatory RNAs and upregulate gene expression for CNS, liver, and haploinsufficiency indications.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors